Intensity Therapeutics, Inc. to Present INVINCIBLE-4 Neoadjuvant Triple-Negative Breast Cancer Study Data for the First Seven (7) Patients After INT230-6 Treatment (Cohort A) in an ePoster Presentation at the European Society of Medical Oncology (ESMO) Meeting
Intensity Therapeutics (INTS) announced positive early data from the INVINCIBLE-4 study, showing a 71% pathological complete response rate in 7 patients with triple-negative breast cancer. The data will be presented at the ESMO 2026 Congress. INT230-6, the company's lead drug candidate, is designed for direct intratumoral injection and has shown promising results in early-stage trials.
How this was made
The 30-second read
Why it matters
The disclosed pCR rates exceed historical benchmarks for neoadjuvant TNBC, potentially accelerating trial enrollment and partnership interest.
Market read
First‑time release of promising early‑stage data for a novel oncology therapy; likely to move INTS stock and influence peer biotech valuations.
What to watch
Dose‑limiting skin reactions and protocol amendment may signal safety concerns that could temper enthusiasm.
Background
Intensity Therapeutics is a late‑stage biotech developing INT230-6, an intratumoral injection combining cisplatin, vinblastine and a diffusion enhancer.
Ticker impact
Intensity Therapeutics disclosed early Phase 2 data showing 71% pathological complete response in the first 7 patients of its INT230-6 neoadjuvant TNBC study.
upward pressure as investors price in higher efficacy expectations
First disclosure of robust pCR rates in a small cohort; biotech stocks typically react sharply to early positive data.
Market effects
May boost confidence in intratumoral drug platforms and raise interest in other neoadjuvant immuno‑chemotherapy combos.
Limited to US biotech sector; no broader regional effect.
Highlights potential for similar approaches in global oncology pipelines.
Counterpoint
Small cohort size and early‑stage data could be over‑optimistic; investors may wait for larger Phase 2/3 results.
Key entities
- companyIntensity Therapeutics
US‑listed biotech (NASDAQ: INTS) developing INT230-6.
- collaboratorSwiss Cancer Institute
Research partner presenting the data at ESMO.
